All In Biotech

Drug Trial Radar · NCT00707499

A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158

A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of BMS 747158 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Nov 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Sep 2007

Primary completion

May 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Lantheus Medical ImagingIndustry
Sponsor type
Industry
First posted
Jul 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to learn the safety and biodistribution of BMS747158 in normal, healthy volunteers.

Conditions

  • Healthy

Interventions

  • BMS747158Drug

    Single dose administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dosimetry analysis following whole body imaging after resting injectionTime frame: Imaging takes place 0 - 310 minutes post injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.